TY - JOUR
T1 - Estrogen receptor-α variants are associated with lipoprotein size distribution and particle levels in women
T2 - The Framingham Heart Study
AU - Demissie, Serkalem
AU - Cupples, L. Adrienne
AU - Shearman, Amanda M.
AU - Gruenthal, Kristen M.
AU - Peter, Inga
AU - Schmid, Christopher H.
AU - Karas, Richard H.
AU - Housman, David E.
AU - Mendelsohn, Michael E.
AU - Ordovas, Jose M.
N1 - Funding Information:
We would like to thank the participants of the Framingham Study. This work was supported by a National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI) Specialized Center of Research in Ischemic Heart Disease (P50 HL63494) and in part by Grants from the NHLBI to DEH (P50-HL63494 and RO1-HL65230). The work is also supported by the NHLBI's Framingham Heart Study (NIH/NHLBI Contract N01-HC-38038 and HL-54776). The Framingham Heart Study is conducted and supported by the NHLBI in collaboration with Boston University.
PY - 2006/3
Y1 - 2006/3
N2 - Plasma lipid profile is affected by endogenous estrogen levels and hormone replacement therapy (HRT). As plasma lipid concentrations have a significant heritable basis and the effects of both endogenous estrogen and use of HRT are mediated by estrogen receptors, we sought to investigate the relationships between polymorphisms in estrogen receptor-α (ESR1) and plasma lipid and lipoprotein concentrations. We analyzed data from 854 women (mean age 52 ± 10 years) from the Framingham Heart Study. A TA repeat in the promoter region, c.30T > C in exon 1, c.454-397T > C, and c.454-351A > G in intron 1, all in linkage disequilibrium (LD), were significantly associated with low-density lipoprotein (LDL) particle size and concentration of small LDL particles. Women with the c.454-397C allele had larger LDL particle size (21.09 ± 0.02 nm versus 21.01 ± 0.03 nm, p = 0.021) concurrent with lower small LDL particle concentration (0.47 ± 0.02 mmol/L versus 0.58 ± 0.03 mmol/L, p = 0.008). Moreover, the TA[L]-c.30C-c.454-397C-c.454- 351G haplotype (frequency, 32%) was associated with lower small LDL particle concentrations (-0.06 ± 0.03 mmol/L change associated with each copy of this haplotype, p = 0.011) when compared to the TA[S]-c.30T-c.454-397T-c.454- 351A haplotype (frequency, 46%), where L and S are long and short TA repeats. Our results suggest that common ESR1 polymorphisms have a significant effect on lipoprotein metabolism in women.
AB - Plasma lipid profile is affected by endogenous estrogen levels and hormone replacement therapy (HRT). As plasma lipid concentrations have a significant heritable basis and the effects of both endogenous estrogen and use of HRT are mediated by estrogen receptors, we sought to investigate the relationships between polymorphisms in estrogen receptor-α (ESR1) and plasma lipid and lipoprotein concentrations. We analyzed data from 854 women (mean age 52 ± 10 years) from the Framingham Heart Study. A TA repeat in the promoter region, c.30T > C in exon 1, c.454-397T > C, and c.454-351A > G in intron 1, all in linkage disequilibrium (LD), were significantly associated with low-density lipoprotein (LDL) particle size and concentration of small LDL particles. Women with the c.454-397C allele had larger LDL particle size (21.09 ± 0.02 nm versus 21.01 ± 0.03 nm, p = 0.021) concurrent with lower small LDL particle concentration (0.47 ± 0.02 mmol/L versus 0.58 ± 0.03 mmol/L, p = 0.008). Moreover, the TA[L]-c.30C-c.454-397C-c.454- 351G haplotype (frequency, 32%) was associated with lower small LDL particle concentrations (-0.06 ± 0.03 mmol/L change associated with each copy of this haplotype, p = 0.011) when compared to the TA[S]-c.30T-c.454-397T-c.454- 351A haplotype (frequency, 46%), where L and S are long and short TA repeats. Our results suggest that common ESR1 polymorphisms have a significant effect on lipoprotein metabolism in women.
KW - Estrogen receptor genetic polymorphisms
KW - Lipid subclasses
KW - Lipoprotein particle size
KW - Women
UR - https://www.scopus.com/pages/publications/30944431727
U2 - 10.1016/j.atherosclerosis.2005.06.008
DO - 10.1016/j.atherosclerosis.2005.06.008
M3 - Article
C2 - 16005459
AN - SCOPUS:30944431727
SN - 0021-9150
VL - 185
SP - 210
EP - 218
JO - Atherosclerosis
JF - Atherosclerosis
IS - 1
ER -